Improving biopharmaceutical properties of Vinpocetine through cocrystallization

SAMUEL GOLOB¹, MIRANDA PERRY², MATTEO LUSI², MICHELE REMO CHIEROTTI³, ISTOK GRABNAR⁴, LUCIA LASSIANI¹, DARIO VOINOVICH¹*, MICHAEL J. ZAWOROTKO²*

¹Department of Chemical and Pharmaceutical Sciences, University of Trieste, Italy
²Department of Chemical & Environmental Sciences, University of Limerick, Limerick, Republic of Ireland
³Department of Chemistry and NIS Centre, University of Torino, Torino, Italy
⁴Faculty of Pharmacy, University of Ljubljana, Askerceva 7, SI-1000 Ljubljana, Slovenia.

ABSTRACT:
Vinpocetine is a poorly water soluble weakly basic drug (pKₐ = 7.1) used for the treatment of several cerebrovascular and cognitive disorders. Since existing formulations exhibit poor bioavailability and scarce absorption, a dosage form with improved pharmacokinetic properties is highly desirable. Cocrystallization represents a promising approach to generate diverse novel crystal forms and to improve the aqueous solubility and in turn the oral bioavailability. In this paper, a novel ionic cocrystal of vinpocetine is described, using boric acid as a coformer, and fully characterized (by means of DSC, solid-state NMR, powder and single crystal XRD, and Powder Dissolution Test). Pharmacokinetic performance was also tested in a human pilot study. This pharmaceutical ionic cocrystal exhibits superior solubilization kinetics and modifies
important pharmacokinetic values such as $t_{\text{max}}$, $c_{\text{max}}$ and AUC of the poorly soluble vinpocetine and it therefore offers an innovative approach to improve its bioavailability.

**Keywords:** Ionic Cocrystal; Vinpocetine; Boric Acid; Bioavailability; Pharmacokinetics

*Correspondence to:* Voinovich Dario (email: vojnovic@units.it); Mike Zaworotko (email: xtal@ul.ie; ph: +353 61 234361; cell: +353 868144150)
INTRODUCTION

Crystalline forms are the preferred dosage forms for active pharmaceutical ingredients (APIs) for use in drug products. Generally single and multicomponent crystals show superior stability to their amorphous counterparts and their synthesis (crystallization) tends to afford highly pure products that are reproducible and scalable.\(^1\) Moreover, different crystal forms can exhibit different physicochemical properties that will affect the pharmacokinetics of the drug. For these reasons, during the early stages of drug development, novel crystal forms of the API are searched for through screening processes and their physicochemical properties are identified.\(^2\)\(^-\)\(^9\) These novel crystal forms might include polymorphs or multi-component crystal such as salts, solvates, hydrates and, more recently, cocrystals. Cocrystals are solids that are crystalline single phase materials composed of two or more different molecular and/or ionic compounds, generally in a stoichiometric ratio, which are neither solvates nor simple salts.\(^10\) The current attraction to cocrystals as novel crystal forms is attributed to their ability to change key properties of APIs via inclusion of additional molecules through reliable, therefore designable, interactions (i.e. supramolecular synthons)\(^11\). A large library of potential coformers can be built using databases containing pharmaceutically approved substances such as the GRAS (generally recognized as safe) list for example, which contains ingredients recognized by the United States Food and Drug Administration (FDA) to be safe under specified conditions. These substances can serve as coformers in order to obtain new crystal forms with improved solubility,\(^12,13\) compressibility,\(^14\) or stability\(^15\) that ultimately impact on bioavailability.\(^16\)

The main challenge during pharmaceutical cocrystal development is the rational selection of coformers for a particular drug molecule, since it is not realistic to screen the whole chemical
catalogue. Following a proven crystal engineering\textsuperscript{17} approach, possible coformers can be chosen to form robust supramolecular interactions (synthons) with the desired drug molecule, taking into consideration supramolecular synthon hierarchy.\textsuperscript{18} This supramolecular synthesis strategy\textsuperscript{11, 19} primarily relies on crystallographic data found in the Cambridge Structural Database (CSD).\textsuperscript{20} This approach, however, has yet to offer clear predictions about whether there will be desirable property improvement in the resulting cocrystals, even though efforts have been made to correlate the physicochemical properties of coformers to those of the resulting cocrystals.\textsuperscript{21}

In particular, amongst pharmaceutical cocrystals, ionic co-crystals have proven to be a viable route to enhance solubility/bioavailability of poorly soluble drugs.\textsuperscript{22} Recently, a pharmaceutical ionic cocystal containing two active ingredients, Entresto\textsuperscript{TM} used to treat chronic heart failure, gained approval from the FDA.\textsuperscript{23}

The target of this study, vinpocetine (Figure 1), is a semisynthetic derivative of the natural alkaloid vincamine, showing a series of pharmacological properties in relation to cerebral circulation and on vascular resistance, particularly in the area of blood vessels.\textsuperscript{24} Vinpocetine has been shown to impact the cerebral circulation and metabolism and improve various types of cerebrovascular circulatory disorders such as the cerebral infarction, cerebral hemorrhage, cerebral arteries cirrhosis\textsuperscript{25} and for the long term treatment of cognitive disorders and related symptoms.\textsuperscript{26} Due to its low aqueous solubility, and extensive first pass metabolism, vinpocetine presents low oral bioavailability (~6.7%)\textsuperscript{27, 28} and, as a consequence, its clinical use is limited. In this context the aim of this investigation is to improve the solubility and bioavailability of vinpocetine with an ionic cocystal.
MATERIALS AND METHODS

Materials

Vinpocetine E.P. grade was a kind gift from Linnea SA (Riazzino-Locarno, CH) with a purity of 99.8% and was used without further purification. Boric acid was supplied by Sigma-Aldrich (St Louis, MO, USA) and used without further purification. Acetonitrile with a purity of 99.9% was supplied by Sigma-Aldrich (St Louis, MO, USA)

Synthesis of Vinpocetine – Boric acid Cocrystal (1)

1 was prepared by slow evaporation using the following procedure: a mixture of vinpocetine (50.1 mg, 0.14 mmol) and boric acid (26.1 mg, 0.42 mmol) was transferred into a glass vial. Subsequently, 14 mL of acetonitrile was added to the solid mixture and stirred for 30 min at 45 °C. The clear solution was then left for slow evaporation under ambient conditions.

Crystal Form Characterization

Single-Crystal X-Ray Diffraction

Single-crystal analysis for 1 was performed on a Bruker-AXS D8 QUEST diffractometer (Bruker, Madison, WI, USA) using a micro focus generator of Mo Kα radiation (λ = = 0.71073 Å) and CMOS PHOTON detector. Data for 1 were collected at 100 K‡. Lattice parameters were determined from least-squares analysis, and reflections were integrated using SAINT (Bruker, Madison, WI, USA). The structure was solved by direct methods and refined by full matrix least squares based on \( F^2 \) using X-Seed software. All non-hydrogen atoms were anisotropically refined. All hydrogen atoms bonded to carbon, nitrogen, and oxygen atoms were placed
geometrically and refined with an isotropic displacement parameter fixed at 1.2 times $Uq$ of the atoms to which they were attached. Hydrogen atoms bonded to methyl groups were placed geometrically and refined with an isotropic displacement parameter fixed at 1.5 times $Uq$ of the carbon atoms.

**Powder X-ray Diffraction (PXRD)**

The cocrystal structure of 1 was characterized using a D8 Bruker X-ray Powder Diffractometer (Bruker, Madison, WI, USA) using Cu Kα radiation ($\lambda = 1.54178$ Å), 40 kV, 40 mA. Data were collected at room temperature on a sample manually ground in an agate mortar. The data were collected over an angular range of 5° to 40° 2θ value in continuous scan mode using a step size of 0.05° 2θ value and a scan rate of 5°/min.

Moreover, a calculated PXRD diffractogram was generated from the single-crystal structure of 1 using Mercury 2.2 (Cambridge Crystallographic Data Centre, Cambridge, UK) and compared with the pattern obtained from the bulk sample.

**Differential Scanning Calorimetry (DSC)**

Differential Scanning Calorimetry was performed on a PerkinElmer Diamond differential scanning calorimeter (PerkinElmer, Waltham, MA, USA) with a scan range of 25 °C–250 °C, scan rate of 10 °C/min under nitrogen atmosphere.

**Solid-state NMR spectroscopy (SSNMR)**

Solid-state NMR spectra were recorded with a Bruker Advance II 400 instrument operating at 400.23, 100.64 and 40.55 MHz for $^1$H, $^{13}$C and $^{15}$N nuclei, respectively. Cylindrical 4 mm o.d.
Zirconia rotors with a sample volume of 80 μL were employed and spun at 12 (13C) or 9 (15N) kHz. All 13C and 15N experiments employed the RAMP-CP pulse sequence (1H 90° pulse of 3.05 μs) with TPPM 1H decoupling with an rf field of 75 kHz during the acquisition period. 13C spectral editing experiments were performed with the CPPISPI pulse sequence with polarization inversion times of 65 and 70 μs for pure vinpocetine and 1, respectively in order to obtain CH3 and Cq positives, CH nulls and CH2 negatives. 13C and 15N chemical shifts were referenced with the resonance of hexamethylbenzene (13C methyl signal at 17.4 ppm) and (NH4)2SO4 (15N signal at -355.8 ppm with respect to CH3NO2).

**Powder Dissolution Test (PDT)**

Prior to dissolution test, the equilibrium solubility was determined at 25°C adding an excess of powder to 20 ml of 0.2 M KH2PO4/0.2 M NaOH (pH 7.4) buffer. The equilibration time was found to be 24h. The dissolution experiments of pure vinpocetine and 1 were performed using 100 ml of pH 7.4 buffer since in previous studies31 it was reported that vinpocetine solubility is highly pH dependent, and is particularly low at intestinal pH values. Each experiment was performed at 37 °C to mimic body temperature. Additionally, the dissolution tests were performed using non-sink conditions to build up the supersaturation, as commonly occurs under finite volume conditions in the gastrointestinal tract, and to allow for possible events such as nucleation, crystallization and precipitation to proceed32. Accordingly, at time zero, a suitable amount of sample (pure drug or cocrystal 1) to give 15 mg of active ingredient, was added to 100 ml phosphate buffer at 37 °C. The crystalline materials were previously sieved and only the powder with a particle size between 50 and 70 μm was used during the dissolution experiments. Each test lasted 5 h, and the uniformity of conditions was constantly ensured by using an impeller.
at a stirring rate of 200 rpm. The equilibrium solubility and the amount of vinpocetine solubilized at each time point was quantified by the previously described method\textsuperscript{33}. Each formulation was tested in triplicate.

**In Vivo absorption studies**

For the *in vivo* study six male volunteers aged between 28 and 55 years were chosen. The study was conducted at the University of Trieste, Italy, following the principles of the Declaration of Helsinki and the International Conference on Harmonization Guidelines. Before the study, a written informed consent was signed by each subject. All the volunteers were prohibited to take medicines, following a one week washout period before the beginning of the present study.

The dose of 10 mg of vinpocetine was administered in a hard gelatin capsule (type 0) with 200 mL of water. After one week of washout period the same procedure was adopted for the test formulation, administering a hard gelatin capsule containing 14 mg cocrystal \textbf{I}, corresponding to 10 mg of vinpocetine. Blood samples (5 ml) were collected in heparinized tubes at interval times of 0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, and 5 h following capsule administration. The collected samples were immediately separated by centrifugation at 2400 g for 10 min, subsequently frozen and stored at -40°C until assayed.

In this study, apovincaminic acid plasma concentrations were monitored, as suggested in the literature\textsuperscript{34}. This choice was made in consideration of the fast metabolic conversion from vinpocetine to apovincaminic acid.

The determination of apovincaminic acid concentration was performed using a previously published HPLC method\textsuperscript{34}. The preparation of the samples for HPLC analysis was performed according to the method reported by Hasa et al\textsuperscript{33}. Briefly, 600 µl methanol were added to 200 µl
plasma, and the resulting mixture was vortexed for 10 min. After centrifugation (2400 g for 6 min), 5 μl of the organic solution was injected.

**Pharmacokinetic Analysis**

A compartmental pharmacokinetic analysis was performed using ADAPT 5 software. One- and two-compartment models with and without absorption lag-time were evaluated and one-compartment model with absorption lag-time was selected for the analysis based on favorable value of Akaike information criterion. The estimated parameters were absorption ($t_{1/2 Ka}$) and elimination ($t_{1/2 Ke}$) half-lives, absorption lag time ($t_{lag}$) and apparent distribution volume ($V_d/F$). Bioavailability parameters, including maximum concentration in plasma ($C_{max}$), time to maximum concentration ($t_{max}$), and area under the plasma concentration-time curve (AUC) were calculated as secondary parameters.

The relative bioavailability after oral administration ($F_{rel}$) was calculated in Eq. 1:

$$F_{rel} = \frac{AUC1}{AUC(\text{vinpocetine})} \quad (1)$$

Descriptive statistics were calculated, and results are reported as means (standard errors). As this was a pilot study, the results were not subjected to any formal statistical test.

**RESULTS AND DISCUSSION**

The potential coformers to cocrystallize with vinpocetine were selected through a supramolecular synthon approach. Vinpocetine is characterized by a tertiary amine and an ester functions that could both act as H-bond acceptors. Hence molecules with H-bond donor groups, such as alcohols and mildly acidic carboxylic acids could be ideal coformer candidates. With this in mind we created a coformer library consisting of GRAS listed substances with hydroxyl functions,
among which boric acid was included. Initial screening experiments in acetonitrile afforded a vinpocetine boric acid ionic cocrystal (1) in 85% yield. Conversely, grinding and slurry were not successful in cocrystal formation.

Solid-state characterizations including X-ray diffraction, SSNMR and DSC were performed on 1.

**X-Ray Diffraction**

Single crystal X-ray diffraction (Figure 2) showed that 1 crystallizes in the monoclinic $P2_1$ space group with two independent vinpocetine molecules per asymmetric unit. The bond distance and residual electron density analysis suggests that the amine function on the two molecules (N11c and N11d) are different, one being neutral and the other being protonated. Indeed the neutral amine acts as an H-bond acceptor for a boronic acid (N···O distance ca. 2.72 Å) while the protonated one is the H-bond donor for a charged assisted interaction with a $B_5H_4O_{10}$ anion (N···O distance ca. 2.81 Å). The anion and boronic acid interact further via an OH···OH H-bond dimer ($R_2^2(8)$ in graph set notation). These supramolecular units containing inorganic and organic components form alternating layers that align parallel to the ab plane, as shown in Figure 2. The experimental PXRD pattern of 1 is reported in Figure 3 and showed a series of sharp diffraction peaks in the 20 theta range 5-40°, suggesting the high crystalline nature of the powdered sample. From Figure 3 it can be also noticed that the experimental PXRD and the calculated patterns of 1 are very similar, indicating absence of significant amounts of impurities.

It must be noted that although the $B_5H_4O_{10}$ anion is a rather common species reported in over 150 structures in the CSD, only in 8 entries the anion co-crystallizes with B(OH)$_3$.

**Differential Scanning Calorimetry**
The solid-state thermal behavior of pure vinpocetine, pure boric acid and 1 was investigated by means of DSC analysis. The DSC curve of pure boric acid shows two endothermal events (Figure 4), the first being the melt occurring at 148 °C followed by a second slightly sharper endothermal event at 159 °C, possibly due to the loss of water molecules and crystal lattice transformations of the initial boric acid into other forms more stable at higher temperatures. Pure vinpocetine shows a single sharp melting peak at 152 °C, indicating the highly crystalline nature of the sample. Vinpocetine starts to decompose after ca. 200 °C (Figure 4). 1 showed a large melting event with a peak at 191°C, which is higher than both pure vinpocetine and boric acid. The broad melting event in the cocrystal, in accordance to some peak broadening showed in experimental PXRD pattern, is possibly due to the different interactions of vinpocetine molecules within the cocrystal lattice (hydrogen-bonded and protonated vinpocetine molecules), a large range of particle size or a less crystalline sample.

**Solid-state NMR spectroscopy**

The SSNMR characterization can facilitate the determination of the moieties present in the crystal structure, in particular in addressing the question of whether the compound discussed herein should be regarded as a molecular cocrystal or as an ionic cocrystal. The difference is subtle since it depends on the hydrogen position along the O···H···N interaction, i.e. whether it is close to oxygen or to nitrogen. This depends on several factors including the relative values of pKa (but pKa can be misleading as it is evaluated with respect to the solvent, usually water, and does not necessarily correlate in the solid-state) the crystal packing and the temperature. It has been reported that NMR spectroscopic methods, such as the measurement of $^{13}\text{C}$ chemical shifts of carboxylic carbon atoms, are good indicators of the protonated state of COOH groups. On the other hand, the $^{15}\text{N}$ chemical shift is remarkably sensitive to the protonation degree of H-
bonded nitrogen atom with shifts at higher or lower frequencies accordingly with the type of nitrogen atom, i.e. whether aromatic or aliphatic. Similar effects are observed upon halogen bond formation or metal coordination which is in agreement with the minor contribution of the lone pair to $\sigma^\circ_{\text{loc}}$ removed by quaternization. The $^{13}$C and $^{15}$N chemical shifts with assignment are reported in Tables 1 and 2, respectively. The $^{13}$C and $^{15}$N CPMAS spectra are reported in Figures 5 and 6, respectively. $^{13}$C spectral editing experiments (spectra reported in the Supporting information Figure S1) were fundamental for the correct assignment of the resonances. For atom numbers we refer to Figure 1: suffix “d” to the number indicates the charged molecule while suffix “a” the neutral one.

The $^{13}$C CPMAS spectra of pure vinpocetine and 1 (Figure 5) can be divided in three main regions: CH$_2$, CH and C$_q$ aliphatic carbons (6-63 ppm), sp$^2$ CH and C$_q$ carbons (107-134 ppm) and CO carbons (161-164 ppm). The spectrum of 1 is characterized by sharp peaks (FWHM around 50-70 Hz) highlighting the high crystallinity of the sample. Furthermore, the splitting of almost all resonances in the spectrum of 1 is in agreement with the presence of two independent molecules in the unit cell ($Z'=$2). The $^{15}$N CPMAS spectrum of pure vinpocetine (Figure 6a) presents two resonances at 4.1 and 113.6 ppm for N11 and N1, respectively both attributed to nitrogen atoms not involved in any interaction. On the other hand, the $^{15}$N CPMAS spectrum of 1 (Figure 6b) shows two signals for the N11 atom at higher frequencies (10.1 and 18.7 ppm) with respect to the pure vinpocetine signal. The former, attributed to N11c, is typical of a nitrogen involved in N···H-O H-bond while the latter, assigned to N11d, is characteristic of a N$^+$-H···O$^-$ interaction. This is a clear indication that a proton transfer took place from the B$_5$H$_4$O$_{10}$ anion to vinpocetine and that there is concomitant presence of both a neutral molecule and a salt in the
unit cell. No significant shifts were observed for the N1 atom on passing from pure vinpocetine to the cocrystal in agreement with the small rearrangement experienced.

**Powder Dissolution Test**

Powder dissolution tests (PDTs) were performed for pure vinpocetine and 1. Pure vinpocetine showed a dissolution profile typical of a poorly soluble drug where concentration of 0.8 mg/L was reached after 5 h (Figure 7). Conversely, in 1 a significant improvement of vinpocetine dissolution rate was achieved. Compared to the original drug, the dissolution behavior of vinpocetine in 1 appears to be superior both in terms of rate and extent of total drug dissolved during the first 5 hours. 1 reaches a concentration of 1.4 mg/L; near to the value for pure vinpocetine Cs, 1.6 mg/L (Figure 7). It is worth noting that the Cs value for pure vinpocetine was reached after 24 hours of dissolution analysis (using the same experimental conditions as the powder dissolution analyses), and is consistent with other values previously reported in literature. The fact that 1 dissolves at a much faster rate than vinpocetine is promising and a faster *in vivo* absorption is expected. In this case the innovative approach of an ionic cocrystallization permits a great improvement of solubilization kinetics with respect to pure crystalline vinpocetine, which can be attributed to different lattice and solvation energies.

**In Vivo absorption studies**

Inspired by these promising *in vitro* dissolution profiles, an *in vivo* pilot study in humans was carried out. A single oral dose of pure vinpocetine was administered to six male volunteers. Following a one week wash out period, the volunteers were then dosed with 1. The plasma profiles are presented in Figure 8 whilst the pharmacokinetic parameters are listed in Table 3.
Our results demonstrate an increase in apovincaminic acid concentration corresponding to improved vinpocetine absorption. In fact, it appears that 1 is more rapidly absorbed, showing a shorter $t_{1/2}$ and $t_{\text{max}}$, and higher $C_{\text{max}}$. In addition to the increased absorption rate, we observed approximately 2-fold improvement in the extent of vinpocetine absorption (Frel). Collectively, these results demonstrate that the improved solubilization kinetics is reflected in an enhanced bioavailability.\textsuperscript{57}

CONCLUSIONS

In summary, we report herein the first ionic cocrystal of vinpocetine, an active ingredient indicated for the improvement of cerebral circulation. As an ionic cocrystal, vinpocetine showed significantly improved dissolution performance with respect to pure vinpocetine. Additionally, the results obtained from the pilot human pharmacokinetic study reveal that the oral bioavailability of vinpocetine is doubled when administered as 1. This study suggests that cocrystallization can be a potential solution to the solubility and bioavailability problems that have thwarted the development of vinpocetine as an effective treatment option for its numerous potential clinical indications. Moreover, these results further verify that cocrystallization is a promising methodology for achieving the desired physicochemical properties of a compound in humans and that these improvements can lead to enhanced bioavailability when applied to compounds that are limited by their solubility.

ACKNOWLEDGMENTS
The authors thank “Università degli Studi di Trieste - Finanziamento di Ateneo per progetti di Ricerca Scientifica - FRA 2015” for funding.

NOTES:
‡Crystallographic Information File for 1 is available from CCDC: ref. number 1498771.

Crystal data 1: colourless plate, 0.200 × 0.100 × 0.100 mm³. Sum Formula C₄₄H₆₀B₆N₄O₁₇, M = 981.82, crystal system monoclinic, P2₁ space group (No. 4), V = 2428.2(3) Å³, Z = 2, Dc = 1.343 g/cm³, F₀₀₀ = 1036, Bruker Quest, MoKα radiation, λ = 0.71073 Å, T = 100(2) K, 2θmax = 55.3°, 29882 reflections collected, 11136 unique (Rint = 0.0494). Final Goof = 1.021, R₁ = 0.0502, wR₂ = 0.0821, R indices based on 8152 reflections with I > 2(I) (refinement on F²), 652 parameters, 1 restraint. Lp and absorption corrections applied, μ = 0.100 mm⁻¹. Absolute structure parameter = 0.2(4).

REFERENCES


43. Diez-Pena E, Quijada-Garrido I, Barrales-Rienda JM, Schnell I, Spiess HW. 2004. Advanced 1H solid-state NMR spectroscopy on hydrogels, 1 -The effect of hydrogen bonding in the


fragments. Crystalline structural characterization and multinuclear NMR studies as evidence of linkage and conformational isomers. RSC Advances 4: 9383-9394.


Table 1. $^{13}$C chemical shifts with assignment of pure vinpocetine and 1.

<table>
<thead>
<tr>
<th>Atom</th>
<th>Type</th>
<th>Vinpocetine</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>C&lt;sub&gt;q&lt;/sub&gt;</td>
<td>164.1</td>
<td>161.9</td>
</tr>
<tr>
<td>2</td>
<td>C&lt;sub&gt;q&lt;/sub&gt;</td>
<td>133.7</td>
<td>135.7</td>
</tr>
<tr>
<td>17</td>
<td>C&lt;sub&gt;q&lt;/sub&gt;</td>
<td>132.4</td>
<td>129.0</td>
</tr>
<tr>
<td>19</td>
<td>C&lt;sub&gt;q&lt;/sub&gt;/CH</td>
<td>127.7</td>
<td>129.0</td>
</tr>
<tr>
<td>5</td>
<td>CH</td>
<td>123.1</td>
<td>124.6</td>
</tr>
<tr>
<td>10</td>
<td>CH</td>
<td>51.0</td>
<td>51.9</td>
</tr>
<tr>
<td>12</td>
<td>CH&lt;sub&gt;2&lt;/sub&gt;</td>
<td>44.7</td>
<td>44.9</td>
</tr>
<tr>
<td>15</td>
<td>C&lt;sub&gt;q&lt;/sub&gt;</td>
<td>37.9</td>
<td>39.1</td>
</tr>
<tr>
<td>14</td>
<td>CH&lt;sub&gt;2&lt;/sub&gt;</td>
<td>27.3</td>
<td>32.1</td>
</tr>
<tr>
<td>25</td>
<td>CH&lt;sub&gt;2&lt;/sub&gt;</td>
<td>25.9</td>
<td>28.6</td>
</tr>
<tr>
<td>9</td>
<td>CH&lt;sub&gt;2&lt;/sub&gt;</td>
<td>20.8</td>
<td>20.4</td>
</tr>
<tr>
<td>13</td>
<td>CH&lt;sub&gt;2&lt;/sub&gt;</td>
<td>16.4</td>
<td>16.6</td>
</tr>
<tr>
<td>23</td>
<td>CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>14.0</td>
<td>15.0</td>
</tr>
<tr>
<td>26</td>
<td>CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>6.7</td>
<td>11.3</td>
</tr>
</tbody>
</table>
Table 2. $^{15}$N chemical shifts with assignment of pure vinpocetine and 1.

<table>
<thead>
<tr>
<th>Atom</th>
<th>Vinpocetine</th>
<th>note</th>
<th>1</th>
<th>note</th>
</tr>
</thead>
<tbody>
<tr>
<td>N1</td>
<td>113.6</td>
<td>Free N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N11</td>
<td>4.1</td>
<td>Free N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N1c/d</td>
<td></td>
<td>110.9/112.7</td>
<td>Free N</td>
<td></td>
</tr>
<tr>
<td>N11c</td>
<td></td>
<td>10.1</td>
<td>N···H-O</td>
<td></td>
</tr>
<tr>
<td>N11d</td>
<td></td>
<td>18.7</td>
<td>N⁺-H···O</td>
<td></td>
</tr>
</tbody>
</table>
FIGURE LEGENDS

**Figure 1.** Structure of vinpocetine with atom numbering scheme.

**Figure 2.** Crystal structure of 1 obtained from Single crystal X-ray diffraction.

**Figure 3.** Profiles of experimental powder X-ray diffractogram of 1 and the calculated diffractogram of 1 based on the single crystal X-ray diffraction data.

**Figure 4.** DCS curves of 1, boric acid and vinpocetine.

**Figure 5.** $^{13}$C (100.64 MHz) CPMAS spectra with assignment of (a) pure vinpocetine and (b) 1, recorded with a spinning speed of 12 kHz.

**Figure 6.** $^{15}$N (40.56 MHz) CPMAS spectra with relevant assignments of (a) pure vinpocetine and (b) 1, recorded with a spinning speed of 9 kHz. Suffix “c” or “d” in the atom number indicates the neutral and charged independent vinpocetine molecule, respectively.

**Figure 7.** Dissolution profile (in pH 7.4 phosphate buffer) of 1 and vinpocetine compared to vinpocetine’s solubility at equilibrium (Cs, equilibration time=24 h)

**Figure 8.** Plasma concentrations of Apovincaminic acid following the oral administration of cocrystal 1 (△) and pure vinpocetine (●).

**Figure S1.** $^{13}$C (100.64 MHz) CPPISPI spectral editing experiment with chemical shifts of (a) pure vinpocetine and (b) 1 recorded with a spinning speed of 12 kHz.
Figure S1. $^{13}$C (100.64 MHz) CPPISPI spectral editing experiment with chemical shifts of (a) pure vinpocetine and (b) 1 recorded with a spinning speed of 12 kHz.